Focus on pushing sales in the US region (a particularly higher margin location when compared to the east),
India, Indonesia and China on the radar,
Key position to get market share in Indonesia,
R&D into faster bone growth (THIS I BELIEVE WILL BE HUGE) and
Tendon regeneration (good to diversify that revenue stream).
Also @bedger from the preso it looks like they have not yet resumed sales in EU, so the growth in revenue for Q2 now in my opinion is more appreciated. If EU can re-commence this Q and be consistent with Qs to come, we could see Annual revenue touch the $3mn mark or get close enough.
We might have to fund growth for atleast 2 years more as @mirri11 stated.
OSX Price at posting:
7.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)